New pill could replace needles for anemia in dialysis patients
NCT ID NCT07300111
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new pill called daprodustat against a standard injectable drug (darbepoetin alfa) for treating anemia in people on hemodialysis. About 100 Chinese adults will take either the pill daily or the injection weekly for 28 weeks. The goal is to see if the pill works just as well at raising hemoglobin levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Daprodustat (a pill that stimulates red blood cell production)
- What this could lead to
- If successful, daprodustat could offer a convenient once-daily pill option to manage anemia in dialysis patients, potentially replacing injectable treatments.
- What could go wrong
- This is a non-inferiority trial, so it may only show that daprodustat is as good as, not better than, existing therapy. It is also limited to Chinese patients on hemodialysis, so results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common period drug double as an anaemia fix?
- A pill vs. a shot: which eases Kidney-Related anemia better?
- Can a pill replace EPO shots for anemia in kidney disease?
- New oral drug could replace injections for kidney anemia
- Hungarian ICU doctors quizzed on blood transfusion habits
- Oxygen-Guided transfusions could cut unnecessary blood use in ICUs